机译:根据基线状态的先进肝细胞癌患者的疗效和安全性:III期索拉非尼亚太审判的子集分析
National Taiwan University Hospital No. 7 Chung-Shan South Road Taipei 10016 Taiwan;
Sun Yat-sen University Cancer Centre Guangzhou China;
First Affiliated Hospital Anhui Medical University Hefei China;
Chi Mei Medical Centre Liou Ying Campus Tainan Taiwan;
Nanjing Bayi Hospital Nanjing China;
Korea University Guro Hospital Seoul South Korea;
Chang Gung Memorial Hospital Tao-Yuan Taiwan;
Kyungpook National University Hospital Daegu South Korea;
Sir Run Run Shaw Hospital Zhejiang China;
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan;
Affiliated Hospital Academy of Military Medical Sciences Beijing China;
Bayer HealthCare Pharmaceuticals Montville NJ United States;
Bayer HealthCare Pharmaceuticals Montville NJ United States;
Bayer Schering Pharma Wuppertal Germany;
Bayer HealthCare Pharmaceuticals Montville NJ United States;
ASAN Medical Center Songpa-gu Seoul South Korea;
Hepatocellular carcinoma; Sorafenib; Subset analyses;
机译:根据基线状态的先进肝细胞癌患者的疗效和安全性:III期索拉非尼亚太审判的子集分析
机译:6519索拉非尼在晚期肝细胞癌(HCC)患者中的疗效和安全性:索拉非尼三期HCC评估随机方案(SHARP)和亚太地区(AP)试验的综合结果
机译:索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性:III期随机,双盲,安慰剂对照试验。
机译:Sorafenib之外的肝细胞癌中的分子疗法:III期试验失败的课程和新型靶标
机译:聚(丙交酯-共-乙交酯)微球体用于局部监测,磁共振成像监测,索拉非尼经导管输送至肝细胞癌。
机译:一项多中心开放标签I期/随机II期研究评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性药代动力学和疗效
机译:索拉非尼在晚期肝细胞癌患者中的疗效和安全性:III期试验的亚分析